Antifungal dosing in critically ill patients

被引：1
作者：
Bergman S.J. [1 ]
Tyagi I. [1 ]
Ronald K. [1 ]
机构：
[1] Division of Infectious Diseases, Southern Illinois University School of Medicine, Springfield, IL 62794, 701 North 1st Street
来源：
Current Fungal Infection Reports | 2010年 / 4卷 / 2期
关键词：
Amphotericin B; Anidulafungin; Antifungals; Caspofungin; Combinations; Critical care; Dose; Echinocandin; Fluconazole; Flucytosine; ICU; Itraconazole; Lipid formulations; Micafungin; Pharmacodynamics; Pharmacokinetics; Posaconazole; Triazole; Voriconazole;
D O I：
10.1007/s12281-010-0012-z
中图分类号：
学科分类号：
摘要：
This article reviews appropriate dosing for antifungals and emphasizes factors specific to the critically ill patient, along with drug pharmacokinetics and pharmacodynamics. The rationale for doses of the echinocandins (caspofungin, micafungin, anidulafungin), triazoles (fluconazole, voriconazole, itraconazole, posaconazole), amphotericin B (including lipid formulations), and flucytosine are discussed. © 2010 Springer Science+Business Media, LLC.
引用
收藏
页码：78 / 86
页数：8
相关论文
共 53 条
[1]  
Morrell M., Fraser V.J., Kollef M.H., Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality, Antimicrobial Agents and Chemotherapy, 49, 9, pp. 3640-3645, (2005)
[2]  
Patel G.P., Simon D., Scheetz M., Et al., The effect of time to antifungal therapy on mortality in candidemia associated septic shock, Am J Ther, 16, pp. 508-511, (2009)
[3]  
Pea F., Viale P., Furlanut M., Antimicrobial therapy in critically ill patients: A review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability, Clinical Pharmacokinetics, 44, 10, pp. 1009-1034, (2005)
[4]  
Walsh T.J., Anaissie E.J., Denning D.W., Et al., Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America, Clin Infect Dis, 46, pp. 327-360, (2008)
[5]  
Lewis II J.S., Graybill J.R., Fungicidal versus fungistatic: What's in a word?, Expert Opin Pharmacother, 9, pp. 927-935, (2008)
[6]  
Wiederhold N.P., Kontoyiannis D.P., Chi J., Prince R.A., Tam V.H., Lewis R.E., Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: Evidence of concentration-dependent activity, Journal of Infectious Diseases, 190, 8, pp. 1464-1471, (2004)
[7]  
Wagner C., Graninger W., Presterl E., Joukhadar C., The echinocandins: Comparison of their pharmacokinetics, pharmacodynamics and clinical applications, Pharmacology, 78, 4, pp. 161-177, (2006)
[8]  
Mazzei T., Novelli A., Pharmacological properties of antifungal drugs with a focus on anidulafungin, Drugs, 69, SUPPL. 1, pp. 79-90, (2009)
[9]  
Constantin J.M., Roszyk L., Guerin R., Et al., Tolerance of caspofungin in intensive care unit: A prospective study, Ann Fr Anesth Reanim, 27, 10, pp. 819-824, (2008)
[10]  
Dowell J.A., Knebel W., Ludden T., Stogniew M., Krause D., Henkel T., Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal, Journal of Clinical Pharmacology, 44, 6, pp. 590-598, (2004)
123456